Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.

Abstract:

SUMMARY:Hepatitis C virus (HCV) genotypes 1 and 4 respond less well to pegylated interferon (pegIFN) plus ribavirin (RBV) therapy. For this reason most studies merge these two genotypes when assessing virological response. However, in most trials the HCV genotype 4 population is rather small, and conclusions are mainly derived from what occurs in HCV-1 patients. All HCV-4 patients coinfected with HIV who received pegIFN plus RBV in two different multicentre studies, PRESCO and ROMANCE, conducted respectively in Spain and Italy, were retrospectively analyzed. Baseline plasma HCV-RNA, proportion of patients with HCV-RNA <10 IU / mL at week 4 (rapid virological response), and HCV-RNA declines >2 logs at week 12 (early virological response, EVR) were all assessed as predictors of sustained virological response (SVR). Overall, 75 patients (60 men) were evaluated. Median age was 40 years and median CD4 count 598 cells / mm(3); 49% had plasma HIV-RNA <50 copies / mL; 71% had elevated liver enzymes and 31% had advanced liver fibrosis (Metavir F3-F4). Median serum HCV-RNA was 5.7 log IU / mL. Rapid virological response was attained by 10 (20%) patients and EVR by 26 (42%). Using intention-to-treat and on-treatment (OT) analyses, SVR was achieved by 21 / 75 (28%) and 21 / 62 (34%) of HCV-4 patients, respectively. In the multivariate analysis (OT), baseline HCV-RNA (OR 0.09 for every log increment; 95% CI: 0.01-0.7) and EVR (OR: 7.08; 95% CI: 1.8-27.2) were significantly and independently associated with SVR. This is the largest series of HIV-infected patients with chronic hepatitis C due to HCV-4 treated with pegIFN plus RBV examined so far and the results show that HCV-4 behaves similarly to HCV-1. Therefore, these patients should be considered as difficult to treat population. Baseline serum HCV-RNA and EVR are the best predictors of SVR in HCV-4 / HIV-coinfected patients.

journal_name

J Viral Hepat

authors

Martín-Carbonero L,Puoti M,García-Samaniego J,De Luca A,Losada E,Quinzan G,Bruno R,Mariño A,González M,Núñez M,Soriano V

doi

10.1111/j.1365-2893.2008.01015.x

subject

Has Abstract

pub_date

2008-10-01 00:00:00

pages

710-5

issue

10

eissn

1352-0504

issn

1365-2893

pii

JVH1015

journal_volume

15

pub_type

临床试验,杂志文章,多中心研究,随机对照试验
  • Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients.

    abstract::Hepatitis Be antigen (HBeAg)-negative chronic hepatitis B (CHB) is associated with hepatitis B virus (HBV) variants harbouring changes in the precore region. Most commonly, a G to A point mutation at nucleotide 1896 (m1896) creates a novel translation stop codon that prevents HBeAg production. In the Mediterranean reg...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.1998.00109.x

    authors: Laras A,Koskinas J,Avgidis K,Hadziyannis SJ

    更新日期:1998-07-01 00:00:00

  • Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients.

    abstract::The limitations of liver biopsy have led to the development of indirect noninvasive models for liver fibrosis assessment. We aimed to evaluate and compare the performance of 30 noninvasive models to predict fibrosis stage in treatment-naïve and treated chronic hepatitis B (CHB) patients. A total of 576 Chinese treatme...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/jvh.13031

    authors: Dong XQ,Wu Z,Zhao H,Wang GQ,China HepB-Related Fibrosis Assessment Research Group.

    更新日期:2019-02-01 00:00:00

  • High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme.

    abstract::To achieve WHO hepatitis C virus (HCV) elimination targets by 2030, mathematical models suggest there needs to be significant scale-up of treatment among people who inject drugs (PWID). We tested whether people who actively inject drugs can be recruited and treated successfully through a community needle and syringe p...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13035

    authors: Schulkind J,Stephens B,Ahmad F,Johnston L,Hutchinson S,Thain D,Ward Z,Vickerman P,Hickman M,Dillon JF

    更新日期:2019-05-01 00:00:00

  • Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection.

    abstract::Hepatitis C virus (HCV) is commonly transmitted by intravenous drug use (IDU) but drug users are under represented in many treatment cohorts, this is because of the assumption of lowered treatment success. We assessed HCV treatment outcomes in active intravenous drug users and patients on opiate substitution therapy. ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01446.x

    authors: Jafferbhoy H,Miller MH,Dunbar JK,Tait J,McLeod S,Dillon JF

    更新日期:2012-02-01 00:00:00

  • GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.

    abstract::GS-9857, an inhibitor of the hepatitis C virus (HCV) nonstructural protein (NS) 3/4A, demonstrates potent activity against HCV genotypes 1-6 and improved coverage against commonly encountered NS3 resistance-associated variants (RAVs). In this study, the safety, tolerability, antiviral activity and pharmacokinetics (PK...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/jvh.12527

    authors: Rodriguez-Torres M,Glass S,Hill J,Freilich B,Hassman D,Di Bisceglie AM,Taylor JG,Kirby BJ,Dvory-Sobol H,Yang JC,An D,Stamm LM,Brainard DM,Kim S,Krefetz D,Smith W,Marbury T,Lawitz E

    更新日期:2016-08-01 00:00:00

  • New HBV subgenotype D9, a novel D/C recombinant, identified in patients with chronic HBeAg-negative infection in Eastern India.

    abstract::Genome diversity is a hallmark of hepatitis B virus (HBV), which allowed its classification into 10 genotypes (A-J) and numerous subgenotypes. Among them, Genotype D is currently segregated into eight subgenotypes (D1-D8). Here, we report the identification and characterization of a novel subgenotype within genotype D...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2012.01655.x

    authors: Ghosh S,Banerjee P,Deny P,Mondal RK,Nandi M,Roychoudhury A,Das K,Banerjee S,Santra A,Zoulim F,Chowdhury A,Datta S

    更新日期:2013-03-01 00:00:00

  • Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation.

    abstract::Antiviral therapy has been shown to improve the prognosis of hepatitis B virus (HBV) DNA-positive hepatocellular carcinoma (HCC) after radical treatment, but antiviral treatments require further optimization. This study aimed to evaluate the efficacies of different antiviral strategies with HCC patients after hepatect...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13236

    authors: Qi W,Zhang Q,Xu Y,Wang X,Yu F,Zhang Y,Zhao P,Guo H,Zhou C,Wang Z,Sun Y,Liu L,Xuan W,Wang J

    更新日期:2020-04-01 00:00:00

  • Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding.

    abstract::The study included 309 HIV-infected pregnant women receiving a lamivudine-containing antiretroviral regimen from week 25 of gestational age until 6 months postpartum, during breastfeeding. Twenty-seven of them (8.7%) were hepatitis B virus surface antigen (HBsAg) positive; at baseline, hepatitis B virus (HBV) DNA leve...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12301

    authors: Pirillo MF,Scarcella P,Andreotti M,Jere H,Buonomo E,Sagno JB,Amici R,Mancini MG,Leone P,Ceffa S,Mancinelli S,Marazzi MC,Vella S,Palombi L,Giuliano M

    更新日期:2015-03-01 00:00:00

  • Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.

    abstract::Long-term functional outcomes of sofosbuvir-based antiviral treatment were evaluated in a cohort study involving 16 Italian centres within the international compassionate use programme for post-transplant hepatitis C virus (HCV) recurrence. Seventy-three patients with cirrhosis (n=52) or fibrosing cholestatic hepatiti...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12712

    authors: Vukotic R,Conti F,Fagiuoli S,Morelli MC,Pasulo L,Colpani M,Foschi FG,Berardi S,Pianta P,Mangano M,Donato MF,Malinverno F,Monico S,Tamè M,Mazzella G,Belli LS,Viganò R,Carrai P,Burra P,Russo FP,Lenci I,Toniutto P

    更新日期:2017-10-01 00:00:00

  • Hepatitis C: an epidemiological review.

    abstract::The aim of the study was to analyse the current literature regarding the mode of transmission of HCV and its global prevalence in different groups of people. A systematic review of the literature on the epidemiology of hepatitis C from 1991 to 2000 using computerized bibliographic databases which include Medline, Curr...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.2002.00329.x

    authors: Memon MI,Memon MA

    更新日期:2002-03-01 00:00:00

  • Prevalence of HBsAg/HBeAg amongst 1 936 801 couples preparing for pregnancy in rural China: An observational study.

    abstract::There are few extant studies on the prevalence of HBV infection in couples preparing for pregnancy. We assessed the prevalence of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) in couples preparing for pregnancy in rural China, and the association between HBV prevalence and the statuses of HBsAg...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12693

    authors: Liu J,Zhang S,Wang Q,Shen H,Zhang M,Zhang Y,Yan D,Liu M

    更新日期:2017-08-01 00:00:00

  • Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry.

    abstract::The impact of direct-acting antiviral (DAA) therapies on fibrosis regression remains uncertain. In the current study, we prospectively evaluated dynamics of liver stiffness by transient elastography (TE) in patients with chronic HCV infection receiving DAA-based treatment. Patients (260) were enrolled in the German He...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13280

    authors: Knop V,Mauss S,Goeser T,Geier A,Zimmermann T,Herzer K,Postel N,Friedrich-Rust M,Hofmann WP,German Hepatitis C-Registry.

    更新日期:2020-07-01 00:00:00

  • Acute hepatitis A in Italy: incidence, risk factors and preventive measures.

    abstract::The incidence of, and risk factors for, acute hepatitis A (AHA) were assessed by using data collected from the Italian surveillance system of acute viral hepatitis (SEIEVA). To this end, a case-control study within a population-based surveillance for acute viral hepatitis was performed. AHA incidence has been estimate...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2008.01025.x

    authors: Tosti ME,Spada E,Romanò L,Zanetti A,Mele A,SEIEVA collaborating group.

    更新日期:2008-10-01 00:00:00

  • Infection with human herpes virus type 8 in an area at high prevalence for hepatitis C virus infection in southern Italy.

    abstract::The Campania Region is a geographical area of southern Italy characterized by high incidence rates of hepatocellular carcinoma and of classic Kaposi's sarcoma. Epidemiological investigations carried out among different population groups in this region have found high prevalence rates of both hepatitis C virus (HCV) an...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2004.00499.x

    authors: Montella M,Serraino D,Crispo A,Romano N,Fusco M,Goedert JJ

    更新日期:2004-05-01 00:00:00

  • Trends of hepatitis A hospitalizations and costs associated with the hospitalization in Spain (2000-2005).

    abstract::The objective of this study was to analyse data related to hospitalization, comorbidities, average stays and costs associated with the hospitalization cases of hepatitis A in Spain, during the period between 2000 and 2005. A retrospective, descriptive study of the epidemiological characteristics of hepatitis A patient...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01075.x

    authors: Arteaga A,Carrasco-Garrido P,de Andres AL,de Miguel AG,Jiménez-García R

    更新日期:2009-04-01 00:00:00

  • Controlled release recombinant human interferon-α2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial.

    abstract::Better convenience and tolerability and sustained therapeutic concentrations might improve interferon (IFN) treatment for chronic hepatitis C virus (HCV) infection. In an open-label, randomized study, controlled release free (chemically unmodified) recombinant human IFN-α(2b) in poly(ether-ester) microspheres (CR-rhIF...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2893.2010.01298.x

    authors: Dzyublyk I,Yegorova T,Moroz L,Popovych O,Zaytsev I,Miroshnichenko V,Kromminga A,Wilkes MM,van Hoogdalem EJ,Humphries JE

    更新日期:2011-04-01 00:00:00

  • Determination of hepatitis B phenotype using biochemical and serological markers.

    abstract::The aim of this study was to assess the validity of categorization of chronic hepatitis B viral infection into stages or phases based upon measures of disease activity and viral load, assuming these phenotypes will be useful for prognostication and determining the need for antiviral therapy. We assessed the phenotype ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12643

    authors: Di Bisceglie AM,Lombardero M,Teckman J,Roberts L,Janssen HL,Belle SH,Hoofnagle JH,Hepatitis B Research Network (HBRN).

    更新日期:2017-04-01 00:00:00

  • Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study.

    abstract::The objectives of this study were to investigate the prevalence of infections with hepatotrophic viruses in an anti-human immunodeficiency virus (HIV)-positive population from Buenos Aires and to compare it among the main risk groups for HIV infection. Four hundred and eighty-four consecutive patients attending the HI...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1046/j.1365-2893.1999.t01-1-6120135.x

    authors: Fainboim H,González J,Fassio E,Martínez A,Otegui L,Eposto M,Cahn P,Marino R,Landeira G,Suaya G,Gancedo E,Castro R,Brajterman L,Laplumé H

    更新日期:1999-01-01 00:00:00

  • Viral load change and sequential evolution of entire hepatitis C virus genome in Irish recipients of single source-contaminated anti-D immunoglobulin*.

    abstract::In hepatitis C virus (HCV) infection, serum viral load is important in the prediction of therapeutic efficacy. However, factors that affect the viral load remain poorly understood. To identify viral genomic elements responsible for the viral load, we investigated samples from a population of Irish women who were iatro...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00645.x

    authors: Itakura J,Nagayama K,Enomoto N,Hamano K,Sakamoto N,Fanning LJ,Kenny-Walsh E,Shanahan F,Watanabe M

    更新日期:2005-11-01 00:00:00

  • Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.

    abstract::To evaluate the cost-effectiveness of ledipasvir/sofosbuvir (LDV/SOF) in treatment-naïve patients with chronic hepatitis C (CHC) genotype 1 (GT1) in the absence or mild fibrosis (F0-F1) versus advanced fibrosis (F2-F4), from the perspective of the Spanish Health System. A Markov model was developed to simulate disease...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12704

    authors: Buti M,Domínguez-Hernández R,Oyagüez I,Casado MA,Esteban R

    更新日期:2017-09-01 00:00:00

  • Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C.

    abstract::Pegylated interferon-α (PEG-IFN-α) plus ribavirin (RBV) treatment fails to achieve a sustained virological response (SVR) in approximately 20-50% of patients with chronic hepatitis C virus (HCV) infection. We assessed the contribution of an anti-IFN-α neutralizing antibody (NAb) on the nonresponse to treatment. NAbs w...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2012.01598.x

    authors: Matsuda F,Torii Y,Enomoto H,Kuga C,Aizawa N,Iwata Y,Saito M,Imanishi H,Shimomura S,Nakamura H,Tanaka H,Iijima H,Tsutsui H,Tanaka Y,Nishiguchi S

    更新日期:2012-10-01 00:00:00

  • Study on the function of circulating plasmacytoid dendritic cells in the immunoactive phase of patients with chronic genotype B and C HBV infection.

    abstract::Hepatitis B virus (HBV) infection induces a wide range of chronic liver injury. The mechanism by which HBV evades the immune surveillance system remains obscure. Plasmacytoid dendritic cells (pDCs) seem to be the major endogenous interferon (IFN)-alpha producers and represent one of the most important cell types in th...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00819.x

    authors: Wang K,Fan X,Fan Y,Wang B,Han L,Hou Y

    更新日期:2007-04-01 00:00:00

  • Hepatitis C and HIV combined screening in primary care: A cluster randomized trial.

    abstract::Hepatitis C virus (HCV) and HIV are major causes of worldwide disease. We aimed to evaluate the effect of a combined screening programme, which included a risk-assessment questionnaire and rapid tests for point-of-care diagnosis, on screening and new diagnosis rates. This prospective, cluster randomized study was carr...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13413

    authors: Martínez-Sanz J,Vivancos MJ,Sánchez-Conde M,Gómez-Ayerbe C,Polo L,Labrador C,González P,Mesa A,Muriel A,Chamorro C,de la Fuente Y,Pérez Elías P,Uranga A,Herrero M,Ares S,Barea R,Moreno S,Pérez-Elías MJ

    更新日期:2021-02-01 00:00:00

  • Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection.

    abstract::In this study, a comprehensive methodology for modelling the hepatitis C virus (HCV) epidemic is proposed to predict the future disease burden and assess whether the recent decline in the incidence of HCV may affect the future occurrence of cirrhosis and hepatocellular carcinoma (HCC) cases. Using the prevalence of HC...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2004.00517.x

    authors: Sypsa V,Touloumi G,Tassopoulos NC,Ketikoglou I,Vafiadis I,Hatzis G,Tsantoulas D,Akriviadis E,Delladetsima J,Demonakou M,Hatzakis A

    更新日期:2004-07-01 00:00:00

  • Methodological issues in papers on IFN therapy: time for reappraisal.

    abstract::We conducted an analytical review of 194 full papers on interferon (IFN) therapy for chronic hepatitis C to evaluate current methodology (i.e. study design, criteria for evaluating the efficacy of therapy and predictors of response). Of the papers evaluated, 64 were randomized controlled trials (RCT), 40 were non-rand...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.2000.00214.x

    authors: Kondili LA,Taliani G,Tosti ME,De Bac C,Pasquazzi C,Mele A

    更新日期:2000-05-01 00:00:00

  • Temporal evolution and global spread of hepatitis B virus genotype G.

    abstract::Hepatitis B virus (HBV) infection is considered a major health problem in the world. HBV is classified into genotypes A to J disseminated worldwide. Genotypes A, D and F are the most frequent in the Western World, B and C are predominant in the East, and E, F, H and J are infrequent and restricted to specific regions....

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13431

    authors: Wolf JM,De Carli S,Pereira VRZB,Simon D,Lunge VR

    更新日期:2021-02-01 00:00:00

  • The epidemiology of hepatitis B virus infection in women of reproductive age in highly endemic areas in China.

    abstract::We describe the epidemiology of hepatitis B virus (HBV) infection among women of reproductive age residing in areas of China that are highly endemic for chronic HBV, and provide evidence useful for decision-makers to guide strategies for preventing mother-to-child transmission of HBV, and assess the impact of perinata...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12757

    authors: Zheng H,Cui FQ,Wang FZ,Huang LF,Shao XP,Du JF,Li J,Zhou Y,Zheng HZ,Zhuo JT,Zeng XX,Zhang GM,Miao N,Sun XJ,Liang XF,Luo HM

    更新日期:2018-01-01 00:00:00

  • The efficacy and safety of treating hepatitis C in patients with a diagnosis of schizophrenia.

    abstract::Treating chronic hepatitis C with pegylated interferon alpha may induce or exacerbate psychiatric illness including depression, mania and aggressive behaviour. There is limited data regarding treatment in the context of chronic schizophrenia. We sought to establish the safety and efficacy of treating patients with sch...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12234

    authors: Mustafa MZ,Schofield J,Mills PR,Priest M,Fox R,Datta S,Morris J,Forrest EH,Gillespie R,Stanley AJ,Barclay ST

    更新日期:2014-07-01 00:00:00

  • Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group.

    abstract::Response to interferon-alpha (IFN-alpha) treatment in hepatitis C is poorer when cirrhosis is present. In the third Australian multicentre hepatitis C trial, Aushep-3, we examined the efficacy and tolerability of an intensive 24-week course of interferon-alpha 2a in Child-Pugh grade A patients with chronic hepatitis C...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1046/j.1365-2893.1997.00062.x

    authors: Farrell G,Cooksley WG,Dudley FJ,Watson K

    更新日期:1997-09-01 00:00:00

  • Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients.

    abstract::To assess the impact of sequential therapy with adefovir dipivoxil (ADV) and pegylated interferon alfa-2a (PEG-IFN) on virological (serum HBV-DNA) and serological (serum HBsAg) response in 20 consecutive HBeAg-negative patients. Patients received ADV for 20 weeks, then ADV and PEG-IFN for 4 weeks and lastly PEG-IFN fo...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.2010.01332.x

    authors: Moucari R,Boyer N,Ripault MP,Castelnau C,Mackiewicz V,Dauvergne A,Valla D,Vidaud M,Chanoine MH,Marcellin P

    更新日期:2011-08-01 00:00:00